Popular Trials
Behavioral Intervention
Peer Support for Inflammatory Bowel Disease Distress
This trial will study IBD Strong Peer, an evidence-based, peer-led intervention to help people with IBD-related psychological distress. It will provide implementation & effectiveness data to improve & adapt the intervention to local needs.
Behavioural Intervention
Fasting-Mimicking Diet for Inflammatory Bowel Disease-Related Depression
This trial is investigating the effects of a fasting mimicking diet on IBD patients who are suffering from symptoms of depression. The goal is to develop a safe and effective treatment to improve mental health in patients with IBD by targeting the gut microbiome through dietary interventions.
Behavioural Intervention
Cognitive Behavioral Therapy vs. Sudarshan Kriya Yoga for Depression in IBD
This trial is testing if talk therapy (CBT) or yoga breathing exercises (SKY) can help reduce anxiety and depression in people with Crohn's disease. The study will compare the effects of these treatments on mental health, quality of life, pain, and fatigue. Yoga has several mechanisms that make it a promising treatment for depression and anxiety, including physical activity, behavioural activation, and mindfulness.
Popular Filters
Trials for Crohn's Disease Patients
Immunoglobulin
Serum Bovine Immunoglobulin (SBI) for Inflammatory Bowel Disease
This trial will test the safety and effectiveness of a protein powder made from cow serum, to see if it can help improve symptoms in children and young adults with inflammatory bowel disease.
Behavioural Intervention
Specialty Medical Homes for IBD and Behavioral Health Conditions
This trial will compare two care strategies for people with IBD and BH, including in-person and technology-supported care. Data will be collected over time through self-report, interviews, and electronic health records.
Behavioural Intervention
Non-Invasive Nerve Stimulation for Pediatric IBD
This trial will test whether transcutaneous vagal nerve stimulation (a non-invasive nerve stimulation through the skin) can decrease inflammation in people with inflammatory bowel disease, leading to improved signs and symptoms of disease.
2'-FL Supplement for Inflammatory Bowel Disease
This trial tests 2'-FL, a sugar from breast milk, as a dietary supplement for young IBD patients in stable remission. It aims to boost good gut bacteria and improve gut health by increasing butyrate levels. 2'-FL, a human milk oligosaccharide, has been shown to promote the growth of beneficial gut bacteria and improve gut health in various studies.
Microbiome Modulator
FMT + Bezlotoxumab for IBD and C. Difficile Infection
This trial is testing whether FMT (fecal microbiota transplantation) plus bezlotoxumab is better than FMT plus placebo for treating IBD (inflammatory bowel disease) and CDI (clostridium difficile infection). Up to 150 patients will be enrolled, and they will be followed for 3 months.
Trials for Ulcerative Colitis Patients
Immunoglobulin
Serum Bovine Immunoglobulin (SBI) for Inflammatory Bowel Disease
This trial will test the safety and effectiveness of a protein powder made from cow serum, to see if it can help improve symptoms in children and young adults with inflammatory bowel disease.
Behavioural Intervention
Specialty Medical Homes for IBD and Behavioral Health Conditions
This trial will compare two care strategies for people with IBD and BH, including in-person and technology-supported care. Data will be collected over time through self-report, interviews, and electronic health records.
Behavioural Intervention
Non-Invasive Nerve Stimulation for Pediatric IBD
This trial will test whether transcutaneous vagal nerve stimulation (a non-invasive nerve stimulation through the skin) can decrease inflammation in people with inflammatory bowel disease, leading to improved signs and symptoms of disease.
2'-FL Supplement for Inflammatory Bowel Disease
This trial tests 2'-FL, a sugar from breast milk, as a dietary supplement for young IBD patients in stable remission. It aims to boost good gut bacteria and improve gut health by increasing butyrate levels. 2'-FL, a human milk oligosaccharide, has been shown to promote the growth of beneficial gut bacteria and improve gut health in various studies.
Trials With No Placebo
Behavioural Intervention
Specialty Medical Homes for IBD and Behavioral Health Conditions
This trial will compare two care strategies for people with IBD and BH, including in-person and technology-supported care. Data will be collected over time through self-report, interviews, and electronic health records.
Monoclonal Antibodies
Vedolizumab for Crohn's Disease
This trial aims to guide doctors on using vedolizumab for patients with small bowel Crohn's Disease. Vedolizumab helps reduce intestinal inflammation by blocking specific cells. The study will also explore new ways to predict and monitor long-term treatment success. Vedolizumab has been a standard treatment for inflammatory bowel diseases like Crohn's disease and ulcerative colitis.
Behavioral Intervention
Nurse Follow-Up for Crohn's Disease
Patients with Inflammatory Bowel Disease (IBD) are frequently hospitalized, with an increased risk of repeat hospitalizations within the same calendar year. Given that hospital readmissions represent a significant burden to patients and the health care system, a standardised pathway for IBD patients discharged from the hospital can have a significant impact on reducing readmission rates, healthcare utilization and patient satisfaction. The primary aim of this study is to evaluate the effectiveness of an IBD post-discharge pathway, involving post-discharge nurse follow-up and electronic monitoring, in reducing IBD readmission rates.
Frequently Asked Questions
Introduction to ibd
What are the top hospitals conducting ibd research?
When it comes to cutting-edge clinical trials focused on inflammatory bowel disease (IBD), several top hospitals are leading the way. Located in Cincinnati, the Cincinnati Children's Hospital Medical Center is dedicated to finding new treatments and therapies for this condition. Currently, they have two active IBD trials underway, representing their commitment to pushing the boundaries of medical research. Similarly, in Pittsburgh at the University of Pittsburgh Medical Center, researchers are conducting two ongoing IBD trials with a similar goal of improving outcomes for patients with this chronic inflammatory condition.
Moving eastward to Boston's prestigious Brigham and Women's Hospital, we find another institution actively engaged in advancing our understanding of IBD through two ongoing clinical trials. These hospitals serve as beacons of hope for those living with IBD by offering innovative treatment options and contributing valuable knowledge to the medical community.
North of the border in Toronto at Mount Sinai Hospital lies another hub of research excellence where scientists tirelessly investigate new approaches for managing IBD. With two active clinical trials centered around this complex condition, they strive to make significant strides towards better patient care.
Notably making an impact from Edmonton is the University of Alberta Hospital, which has taken up a crucial role in combating IBD. Although currently focusing on one active trial related to this challenging gastrointestinal illness that affects millions worldwide; their dedication speaks volumes about their commitment towards relieving those suffering from its debilitating symptoms.
These esteemed institutions represent promising avenues for future breakthroughs that could transform the lives of individuals grappling with IBD across North America and beyond. Through pioneering research initiatives like these, we move closer than ever before toward uncovering effective treatments and ultimately working toward a cure - instilling optimism among both patients and healthcare professionals alike
Which are the best cities for ibd clinical trials?
When it comes to clinical trials for IBD, several cities lead the way in research and development. Boston, Massachusetts; New york, New York; Cincinnati, Ohio; Edmonton, Alberta; and Palo Alto, California all have active trials focusing on different aspects of IBD treatment. These trials explore a range of interventions such as Vitamin D3 supplementation, high definition colonoscopy procedures, remote monitoring techniques, fucosyllactose supplementation, plant-based fasting-mimicking diets and more. With their commitment to advancing knowledge about IBD management and treatment options through clinical trials, these cities provide opportunities for individuals seeking innovative approaches to managing this condition.
Which are the top treatments for ibd being explored in clinical trials?
Clinical trials are paving the way for innovative treatments in the field of inflammatory bowel disease (IBD). One promising contender is vedolizumab, which has shown significant potential with several ongoing trials. Another notable option being explored is ustekinumab, demonstrating its effectiveness in managing IBD through clinical studies. Additionally, tofacitinib showcases promise as a therapeutic approach for IBD patients based on current research findings. These top treatments offer hope and progress towards improving the lives of individuals affected by IBD.
What are the most recent clinical trials for ibd?
Exciting advancements are being made in the field of inflammatory bowel disease (IBD) through recent clinical trials. One notable trial investigates the potential benefits of Aspirin 81Mg Ec Tab for IBD patients, with promising results emerging from Phase 3 studies. Additionally, Methylprednisolone has shown promise as a treatment option during Phase 1 trials for individuals with IBD. Another significant trial focuses on Bezlotoxumab and its effects on IBD patients, showing encouraging outcomes during Phase 2 research. These groundbreaking studies offer hope for improved management and treatment options for those living with IBD.
What ibd clinical trials were recently completed?
Recently completed clinical trials in the field of inflammatory bowel disease (IBD) have made significant strides in advancing treatment options for patients. Notably, a trial sponsored by AbbVie Inc., investigating the effectiveness of risankizumab for Crohn's disease and ulcerative colitis, concluded successfully. Additionally, Janssen Research & Development recently completed an important trial evaluating ustekinumab as a potential therapy for IBD. These recent advancements highlight the ongoing commitment to finding innovative approaches to managing and mitigating the impact of IBD on patients' lives.